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The safety and efficacy of a newly developed in- 
travenous formulation of the nonionic contrast 
agent gadolinium diethylenetriaminepentaaacetic 
acid-bis(methy1amide). formulated as gadodia- 
mide injection, was investigated. In 30 patients 
who underwent spin-echo magnetic resonance 
(MR) imaging before and after contrast agent en- 
hancement, the enhanced images had character- 
istics judged similar to those of images enhanced 
by means of available gadolinium compounds. In 
15 patients, contrast agent administration was of 
major diagnostic help, either revealing lesions 
not apparent without enhancement or providing 
important lesion characterization. In 12 pa- 
tients, the lack of abnormal enhancement pat- 
terns was important in excluding the presence of 
disease. In three patients. the contrast agent did 
not provide information additional to that ob- 
tained with the unenhanced T1- and T2-weight- 
ed images. No clinically significant changes were 
observed in vital signs, neurologic status, or lab- 
oratory results. The authors conclude that, in 
this limited series, gadodiamide injection proved 
to be a safe and useful MR imaging contrast 
agent for evaluation of the central nervous sys- 
tem and surrounding structures. 
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THIS MULTICENTER STUDY EVALUATED the im- 
aging efficacy and clinical safety of a new nonionic 
gadolinium chelate contrast agent for magnetic res- 
onance (MR) imaging, gadolinium diethylenetria- 
minepentaacetic acid-bls(methy1amide) (abbreviat- 
ed Gd-DTPA-BMA). Formulated as gadodiamide in- 
jection, it was developed by Salutar (Sunnyvale, 
Calif). Animal studies suggested that because of its 
nonionic nature and strong chelation (median le- 
thal dose in mice, 34.4 mmol/kg), it will likely prove 
to be a safe MR contrast agent (Salutar, data on file, 
1989); this was also supported by the phase I trial 
of the agent (1). 
0 MATERIALS AND METHODS 
Patients were selected from those referred for 
MR imaging with a known or suspected diagnosis 
of a space-occupying lesion in or adjacent to the 
central nervous system. Patients were not required 
to abstain from food or medications before the ex- 
amination. Informed consent was obtained in each 
case, and the protocol conformed to U S .  Food and 
Drug Administration guidelines and was approved 
by the University of Michigan Institutional Review 
Board. 
A brief neurologic examination was performed, 
and medical history, vital signs, and urine and 
blood samples were obtained before contrast agent 
administration, with all but the history repeated af- 
terward. The few exceptions to this procedure will 
be described. After contrast agent injection, pa- 
tients were closely questioned regarding possible 
adverse reactions. 
Patients with significant known or suspected liv- 
er disease, renal dysfunction, hemolytic anemia, 
uncontrolled seizures, pregnancy, and certain oth- 
er medical conditions were excluded. The laborato- 
ry tests included a complete blood count, liver and 
kidney function tests, serum iron levels, and uri- 
nalysis. Substantial changes in laboratory results 
were defined a s  a change of more than 50% of the 
difference between the low and high values of the 
normal range. Vital signs were measured and a 
neurologic evaluation was done shortly before im- 
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aging. Pre-contrast-enhancement images were ob- 
tained with both T1- and T2-weighted spin-echo 
sequences. Postcontrast images were obtained with 
T1 -weighted spin-echo sequences in the same 
plane and with the same parameters as the precon- 
trast study. Section thickness, section spacing, and 
the imaging plane(s) were chosen on the basis of 
clinical history in each case. 
nously at a dose of approximately 0.1 mmol/kg 
(range, 08-0.1 1 mmol/kg). Immediately after con- 
trast agent injection, approximately 5 mL of 0.9% 
normal saline was injected to ensure that all drug 
was cleared from the infusion tubing. 
Vital signs were measured at approximately 5, 
30, and 120 minutes after contrast agent injection. 
Two hours after injection, a repeat neurologic ex- 
amination was performed. Approximately 24 hours 
after injection, repeat urine and blood samples 
were obtained. Discomfort or complaints of the pa- 
tients were solicited and recorded throughout the 
study. Evaluation for adverse effects related to con- 
trast agent administration was based on the pa- 
rameters of Karch and Lasagna (2). 
(A.M.A., S.R.A.) experienced in interpretation of 
MR images. The efficacy of the agent was subjec- 
tively evaluated and a consensus reached. For pur- 
poses of this report, the following criteria were used 
to assess the efficacy of the contrast agent: (a) pro- 
vision of additional information toward diagnosis, 
[b) increase in the confidence of the diagnosis, 
(c) detection of lesions not otherwise visible, and 
(d) provision of important information for greater 
characterization of lesions seen with other pulse 
sequences. In cases in which lesion enhancement 
was evident, the agent was judged to be of (a) no 
help, (b) minor help, (c) moderate help, or (d) major 
help in diagnosis. In those cases that did not show 
abnormal enhancement, a judgment was made as 
to whether the agent was helpful in excluding sus- 
pected disease (eg, in cases of pituitary adenoma or 
acoustic neuroma). 
Included in the study were 17 men and 13 wom- 
en, ages ranging from 19 to 84 years (mean, 50 
years). Images of the brain, pituitary gland, acous- 
tic nerves, and/or foramen magnum were obtained 
in 20 patients; images of the spine were obtained in 
nine patients and of the skull base in one patient. 
The studies were requested for a variety of reasons, 
broadly categorized as follows (with some overlap): 
to rule out metastasis (n = 6), to rule out tumor in 
the cerebellopontine angle (n = 5), to rule out pitu- 
itary adenoma (n = 3). to rule out tumor (n = 5), to 
follow up tumor (n = 5), to differentiate disk abnor- 
mality from scar or tumor (n = 4), to rule out ab- 
scess (n = 1). and to follow up head and neck tumor 
(n = 1). 
0 RESULTS 
Gadodiamide injection was administered Intrave- 
Images were reviewed by two radiologists 
Study Protocol 
Eighteen patients were imaged on a 1.5-T sys- 
tem (Signa; GE Medical Systems, Milwaukee), 10 on 
a 0.35-T system (MT/S; Diasonics, Toshiba Ameri- 
ca MRI, South San Francisco, Calif), one on a 0.5-T 
system (HP: Picker, Cleveland), and one on both the 
1.5-T and 0.35-T systems. Eleven patients received 
the contrast agent infusion over a 30- 180-second 
duration (average, 101 seconds). The remainder re- 
ceived the injection in 30 seconds or less (average, 
21 seconds). 
All but one patient were imaged with T1- and T2- 
weighted sequences before contrast agent injection 
and with T1 -weighted sequences after injection; 
the exception was imaged with T1-weighted se- 
quences before and after contrast agent injection. 
In one patient, the postcontrast neurologic exami- 
nation was omitted, and in another patient the fol- 
low-up neurologic evaluation was performed after a 
delay of 24 hours. 
formed before contrast agent injection: blood count 
in one patient, urinalysis in two patients, biochem- 
istry studies in one patient, and serum iron level in 
one patient. In one additional patient, results of 
laboratory tests performed 2 months before the 
study were used and a serum iron level was not 
available; in another patient, the poststudy blood 
count was obtained after a 1 -week delay. Hence, in 
three patients serum iron levels were not obtained 
before contrast agent injection. Measurement of di- 
rect bilirubin was incomplete in the majority of pa- 
tients because of difficulties related to transporting 
the blood specimens to the distant laboratory. 
Image Evaluation 
MR images after administration of gadodiamide 
injection (Figs 1-3) showed enhancement patterns 
and imaging characteristics similar to what would 
be expected from the use of several existing gado- 
linium compounds (3-26) such as  gadopentetate di- 
meglumine (Magnevist; Berlex Laboratories, 
Wayne, N J )  and gadolinium tetraazacyclododecan- 
etetraacetic acid (DOTA), a macrocyclic gadolinium 
compound available in France, with contrast be- 
havior similar to that of gadopentetate dimeglu- 
mine. In six subjects, contrast agent administration 
was of major diagnostic help, either revealing le- 
sions not apparent without enhancement or pro- 
viding important lesion characterization (Figs 1-3). 
In seven patients, this was true to a moderate de- 
gree, and in two subjects the contrast agent was 
thought to be of minor help. In 12 patients, the lack 
of abnormal enhancement patterns was important 
in excluding the presence of disease. In three pa- 
tients, the agent was judged to be of no significant 
help, since the pattern of contrast enhancement 
(two patients) or the lack of enhancement (one pa- 
tient) added no new information when compared 
with nonenhanced images. 
Clinical and Laboratory Evaluation 
Clinically, our patients experienced no major ad- 
verse reactions. No changes in vital signs were 
judged clinically significant. The average change in 
systolic blood pressure was 6 mm Hg, in diastolic 
blood pressure 5 mm Hg, in pulse rate four beats 
per minute, and in respiration two breaths per min- 
ute. Minor redness, swelling, or bruises at the injec- 
tion site were noted in three patients: in two, this 
The following laboratory tests were not per- 
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Figure 1. Thyroid carcinoma metastasis. T1-weighted images (0.35 T, TR msec/TE msec = 500/30) of a 70-year-old man 
with a history of thyroid carcinoma. (a) Coronal precontrast image demonstrates a large right calvarial mass with high-sig- 
nal-intensity areas suggestive of hemorrhage: the mass proved to be a metastasis from thyroid carcinoma. The major in- 
tracranial component is isointense with brain. (b) After contrast agent administration, the intracranial portion of the le- 
sion is enhanced. 
was probably related to extravasation of saline af- 
ter contrast agent injection: in the third patient, the 
minor symptoms may have been related to infusion 
of the agent. Two patients complained of mild head- 
aches: in both cases, these headaches resembled 
headaches they had experienced in the past, for 
which they were being evaluated. Three patients 
reported other minor symptoms thought to be of no 
practical consequence and likely not related to the 
physiologic effects of the contrast agent. 
Nine patients had abnormal neurologic examina- 
tion results, with findings usually related to the dis- 
ease process for which they were referred for MR 
imaging. Except for the one patient who became 
drowsy as a result of two 10-mg doses of diazepam 
administered orally for claustrophobia, there were 
no changes in the neurologic examination results 
before and after contrast agent administration. 
There were no substantial changes in laboratory 
results in 13 patients. One patient had a dramatic 
increase in platelet count (to 489,000), but the 
count was normal at retest several weeks later: the 
significance of the finding is unknown. Two pa- 
tients had moderate increases in serum y-glutamyl- 
transferase to abnormal levels [the change was 34 
IU/L for both: the pretest level in one of these pa- 
tients was also abnormal). There were no consis- 
tent changes in the serum iron levels. In 12 pa- 
tients the serum iron level increased, and in 15 it 
decreased: in three patients serum iron levels were 
not determined before contrast agent injection. In 
eight patients, the change was substantial. The av- 
erage change in serum iron level was 5%. and the 
average of the magnitude of changes in serum iron 
level was 32%. Thegreatest change was 97%, from 
72 to 142 pg/dL [ 13 pmol/L to 25 pmol/L) [both val- 
ues are within normal limits). Six patients had ab- 
normally high serum iron levels after contrast 
agent injection, and two had levels that were below 
normal. Of the six patients with elevated levels, two 
also had high serum iron levels before contrast 
agent administration. 
0 DISCUSSION 
The sensitivity and specificity of MR imaging 
has improved with the introduction of gadolinium 
contrast agents (3-25). Enhancement of central 
nervous system lesions on T1 -weighted images af- 
ter gadolinium administration usually indicates an  
abnormal blood-brain barrier with viable blood 
supply or hypervascularity. Although MR images 
have proved highly sensitive for detection of lesions 
in, or closely related to, the central nervous system, 
experience with gadolinium contrast enhancement 
has shown that in some instances lesions that were 
not otherwise evident become apparent after con- 
trast agent administration. For example, neuromas 
(1 4), pituitary microadenomas [ 1 6), and meningio- 
mas (1 3,15) are more readily seen after contrast 
agent administration. In addition, gadolinium-en- 
hanced imaging has improved the delineation, and 
aided in the temporal characterization, of lesions 
with an actively disrupted blood-brain barrier. 
Such lesions include multiple sclerosis (21). ab- 
scess (6,26), ischemia (22), and cerebritis (26). Fi- 
nally, definition of the extent of tumors and their 
characterization can at times be improved, increas- 
ing diagnostic accuracy (4-1330). The absence of 
Volume 1 Number 1 JMRl 59 
a. b. 
C. d. 
Figure 2. Craniovertebral junction meningioma. T1-weighted images (0.35 T. 500/40] of a 45-year-old woman with neck 
pain demonstrate an enhancing lesion that proved to be a meningioma. (a] Precontrast sagittal image shows an  extradural 
mass isointense with neural tissue (arrows], displacing the cervicomedullary junction. (b) Postcontrast image shows heter- 
ogeneous enhancement of the mass. (c) Precontrast axial image confirms the presence of the mass (arrows], which dis- 
places the upper cervical spinal cord to the left. (d) Postcontrast image again demonstrates enhancement of the mass. 
areas of abnormal signal intensity on images ob- 
tained with all sequences (including T1 -weighted 
sequences) after administration of a gadolinium 
compound provides valuable clinical information 
for excluding suspected disease. In cases in which 
questionable areas of signal-intensity abnormality 
are noted on previous unenhanced images, gadolin- 
ium can help determine the true nature of lesions 
or confirm their absence. 
pounds, has unpaired electrons, resulting in para- 
magnetism that reduces the T1 and T2 of protons 
Gd-DTPA-BMA, like other gadolinium com- 
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Figure 3. Cystic astrocytoma. T1-weighted images (0.35 T, 567/20) of a 68-year-old woman with a known cystic astrocy- 
toma. (a) Precontrast axial image reveals a well-defined inhomogeneous mass In the superior vermis. (b) Postcontrast im- 
age demonstrates an irregular rim of enhancement with a central area of decreased signal intensity compatible with tu- 
mor surrounding a cystic or necrotic component. 
(27-29). Its relaxivity in water at 10 MHz is 4.6 
mm-l sec-I for T1 and 5.1 mm-l sec-l for T2 ( l ) ,  
which is similar to that of gadopentetate dimeglu- 
mine. Thus, at pharmacologically achieved concen- 
trations, the agent can be expected to increase MR 
signal intensity on T1-weighted images at sites in 
the central nervous system where it accumulates 
because of lesion vascularity or breakdown of the 
blood-brain barrier. Animal and healthy human 
volunteer trials suggest that as a result of the non- 
ionic structure (Salutar, data on file, 1989: 11, 
strong chelation, and reduced osmolarity of Gd- 
DTPA-BMA, it will be well tolerated in humans (1). 
In mice, the median lethal dose for gadodiamide in- 
jection is 34.4 mmol/kg, which is substantially 
higher (ie, less toxic] than for gadolinium com- 
pounds currently available (Salutar, data on file, 
1989; Berlex, Wayne, N J ,  package insert for Mag- 
nevist, 1990). 
Gadodiamide injection was found to be an effica- 
cious agent, subjectively increasing diagnostic yield 
in the large majority of the patients studied. Its be- 
havior was similar to what we have experienced 
and the literature has described regarding the 
available compounds gadopentetate dimeglumine 
and Gd-DOTA (3-26). We encountered no serious 
acute laboratory or clinical side effects in this limit- 
ed number of patients that would preclude its use. 
All reported adverse symptoms were mild, and in 
many cases were most likely not directly related to 
administration of contrast agents. In our opinion, 
none of these symptoms suggested hazards that 
would preclude routine clinical use of the com- 
pound. Eight patients had substantial changes in 
serum iron levels. It is uncertain whether these 
were related to the agent or to normal physiologic 
variation. Transient increases in serum iron level 
of doubtful clinical significance have been reported 
with gadopentetate dimeglumine at a dose of 0.25 
mmol/kg (30,31). The significance of the platelet- 
count abnormality in one patient is not known. 
The major limitations of this study are the small 
size of the patient group, the subjective nature of 
the efficacy determination, and the lack of a direct 
comparison with other agents such as  gadopente- 
tate dimeglumine. The first limitation will likely be 
mitigated by results from other institutions; a total 
of 439 patients were studied at the 15 institutions. 
Our efficacy determinations were subjective. We 
believe that while other experienced radiologists 
might have assigned a small number of individual 
patients differently, the overall conclusions regard- 
ing the efficacy of gadodiamide injection are valid 
and supported by the results of these 30 imaging 
studies. We did not attempt to directly access 
changes in clinical patient treatment that may 
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have resulted from use of contrast agent. 
In conclusion, gadodiamide injection in this limit- 
ed series proved to be a safe, well-tolerated, and ef- 
ficacious MR imaging contrast agent for optimal 
evaluation of the central nervous system and adja- 
cent structures, and the findings support its fur- 
ther development. The patterns of enhancement 
appear similar to those of the already approved 
agents gadopentetate dimeglumine and Gd-DOTA. 
If further experience and results from other centers 
corroborate these results, gadodiamide injection 
will likely prove to be a useful MR contrast agent, 
after regulatory approval. 0 
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